Patrick W. Heiser

ORCID: 0000-0002-8831-4973 · 4 papers in corpus
nonrandomized-trial 2026
Safety evaluation of a novel progesterone vaginal ring (PVR) for luteal phase support: SARA trial
Drug delivery and translational research ·doi:10.1007/s13346-026-02158-x

After manufacturing changes, the safety and tolerability of the progesterone vaginal ring (PVR) was compared to findings from the similarly designed phase 3 trial. This prospective, open-label, single-arm, multi-center U.S. trial was conduc…

rct 2025
Impact of gonadotropin selection on risk of ovarian hyperstimulation syndrome in predicted high responders: a Menopur in Gonadotropin-releasing hormone Antagonist Single Embryo Transfer-High Responder trial analysis
F&S reports ·doi:10.1016/j.xfre.2025.07.003

OBJECTIVE: To evaluate the risk of ovarian hyperstimulation syndrome (OHSS) with highly purified human menopausal gonadotropin (HP-hMG) or recombinant follicle-stimulating hormone (rFSH) for controlled ovarian stimulation in patients predic…

rct 2025
Quinagolide vaginal ring for reduction of endometriotic lesions: Results from the QLARITY trial
European journal of obstetrics, gynecology, and reproductive biology ·doi:10.1016/j.ejogrb.2025.113946

BACKGROUND: This study evaluated the effectiveness of quinagolide vaginal ring on reducing total lesion size in endometrioma, deep infiltrating endometriosis (DIE), and adenomyosis, as assessed using high-resolution MRI and imaging biomarke…

rct 2024
O-021 Magnetic Resonance Imaging (MRI) evaluation of Quinagolide Vaginal Ring (QVR) treatment on endometrioma, Deep Infiltrating Endometriosis (DIE), and adenomyosis lesion characteristics: QLARITY trial results
·doi:10.1093/humrep/deae108.021

Abstract Study question Can MRI provide a useful assessment of changes to endometrioma, DIE, and adenomyosis lesion burden resulting from QVR treatment? Summary answer MRI successfully measured changes in the number, size, diffusion, and pe…